Lymphoma cell-of–origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts

Grace Gifford, Sara Gabrielli, Anthony Gill, Matthew Greenwood, Kelly Wong, Giles Best, David Nevell, Kirsty McIlroy, David Kliman, Louise Ilmay-Gillespie, Campbell Tiley, Sunaina Miranda, Tasman Armytage, William Stevenson

Research output: Contribution to journalLetterpeer-review

7 Citations (Scopus)

Abstract

Cell-of-origin (COO) assignment for diffuse large B-cell lymphoma (DLBCL) using formalin-fixed paraffin embedded (FFPE) lymph nodes by Lymph2Cx assay on the NanoStringnCounter was comparable to microarray-based methods using fresh tissue in demonstrating prognostic significance (Scott et al, 2014). The assay provided an accessible means of translating gene expression profiling into standard practice with both prognostic and therapeutic implications (Pasqualucci et al, 2011; Dunleavy et al, 2014). We sought to determine if clinically meaningful results were obtainable from small core biopsies and EDTA (ethylenediaminetetraacetic acid) decalcified trephine biopsies.
Original languageEnglish
Pages (from-to)272-275
Number of pages4
JournalBritish Journal of Haematology
Volume181
Issue number2
DOIs
Publication statusPublished - Apr 2018
Externally publishedYes

Keywords

  • gene expression
  • lymphomas
  • molecular diagnostics

Fingerprint

Dive into the research topics of 'Lymphoma cell-of–origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts'. Together they form a unique fingerprint.

Cite this